scholarly journals Personalized Virus Load Curves for Acute Viral Infections

Viruses ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1815
Author(s):  
Carlos Contreras ◽  
Jay M. Newby ◽  
Thomas Hillen
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Patient Specific ◽  
Model Parameters ◽  
Specific Level ◽  
Large Variability ◽  
Virus Load ◽  
Target Model ◽  
Load Function ◽  
Specific Virus

We introduce an explicit function that describes virus-load curves on a patient-specific level. This function is based on simple and intuitive model parameters. It allows virus load analysis of acute viral infections without solving a full virus load dynamic model. We validate our model on data from mice influenza A, human rhinovirus data, human influenza A data, and monkey and human SARS-CoV-2 data. We find wide distributions for the model parameters, reflecting large variability in the disease outcomes between individuals. Further, we compare the virus load function to an established target model of virus dynamics, and we provide a new way to estimate the exponential growth rates of the corresponding infection phases. The virus load function, the target model, and the exponential approximations show excellent fits for the data considered. Our virus-load function offers a new way to analyze patient-specific virus load data, and it can be used as input for higher level models for the physiological effects of a virus infection, for models of tissue damage, and to estimate patient risks.

scholarly journals Personalized Virus Load Curves of SARS-CoV-2 Infection

2021 ◽  
Author(s):  
Thomas Hillen ◽  
Carlos Contreras ◽  
Jay M. Newby
Keyword(s):  
Influenza A ◽  
Patient Specific ◽  
Model Parameters ◽  
Physiological Effects ◽  
Specific Level ◽  
Macaque Monkeys ◽  
Virus Load ◽  
Load Function ◽  
Load Analysis ◽  
Intuitive Model

AbstractWe introduce an explicit function that describes virus-load curves on a patient-specific level. This function is based on simple and intuitive model parameters. It allows virus load analysis without solving a full virus load dynamic model. We validate our model on data from influenza A as well as SARS-CoV-2 infection data for Macaque monkeys and humans. Further, we compare the virus load function to an established target model of virus dynamics, which shows an excellent fit. Our virus-load function offers a new way to analyse patient virus load data, and it can be used as input to higher level models for the physiological effects of a virus infection, for models of tissue damage, and to estimate patient risks.

scholarly journals Personalized Virus Load Curves of SARS-CoV-2 Infection

2021 ◽  
Author(s):  
Thomas Hillen ◽  
Carlos Contreras ◽  
Jay M. Newby
Keyword(s):  
Influenza A ◽  
Patient Specific ◽  
Model Parameters ◽  
Physiological Effects ◽  
Specific Level ◽  
Macaque Monkeys ◽  
Virus Load ◽  
Load Function ◽  
Load Analysis ◽  
Intuitive Model

AbstractWe introduce an explicit function that describes virus-load curves on a patient-specific level. This function is based on simple and intuitive model parameters. It allows virus load analysis without solving a full virus load dynamic model. We validate our model on data from influenza A as well as SARS-CoV-2 infection data for Macaque monkeys and humans. Further, we compare the virus load function to an established target model of virus dynamics, which shows an excellent fit. Our virus-load function offers a new way to analyse patient virus load data, and it can be used as input to higher level models for the physiological effects of a virus infection, for models of tissue damage, and to estimate patient risks.

scholarly journals A Standard Virus Load Function

2020 ◽  
Author(s):  
Thomas Hillen
Keyword(s):  
Virus Infection ◽  
Dynamic Model ◽  
Tissue Damage ◽  
Influenza A ◽  
Treatment Strategies ◽  
Virus Dynamics ◽  
Physiological Effects ◽  
Macaque Monkeys ◽  
Virus Load ◽  
Load Function

AbstractThe idea is to design a simple function that can describe typical virus-load curves without solving a full virus load dynamic model. We present such a standard virus load function and validate it on data from influenza A as well as SARS-CoV-2 infection data for Macaque monkeys and humans. Further, we compare the virus load function to an established target model of virus dynamics as presented by A. Smith in [1]. This virus-load function can be used as input to higher level models for the physiological effects of a virus infection, for models for tissue damage, and to develop treatment strategies.

scholarly journals A flexible framework for sequential estimation of model parameters in computational hemodynamics

2020 ◽  
Vol 7 (1) ◽  
Author(s):  
Christopher J. Arthurs ◽  
Nan Xiao ◽  
Philippe Moireau ◽  
Tobias Schaeffter ◽  
C. Alberto Figueroa
Keyword(s):  
Unscented Kalman Filter ◽  
Three Dimensional ◽  
Synthetic Data ◽  
Sequential Estimation ◽  
Wall Material ◽  
Patient Specific ◽  
Model Parameters ◽  
Computational Framework ◽  
Lumped Parameter ◽  
Estimation Of Model Parameters

AbstractA major challenge in constructing three dimensional patient specific hemodynamic models is the calibration of model parameters to match patient data on flow, pressure, wall motion, etc. acquired in the clinic. Current workflows are manual and time-consuming. This work presents a flexible computational framework for model parameter estimation in cardiovascular flows that relies on the following fundamental contributions. (i) A Reduced-Order Unscented Kalman Filter (ROUKF) model for data assimilation for wall material and simple lumped parameter network (LPN) boundary condition model parameters. (ii) A constrained least squares augmentation (ROUKF-CLS) for more complex LPNs. (iii) A “Netlist” implementation, supporting easy filtering of parameters in such complex LPNs. The ROUKF algorithm is demonstrated using non-invasive patient-specific data on anatomy, flow and pressure from a healthy volunteer. The ROUKF-CLS algorithm is demonstrated using synthetic data on a coronary LPN. The methods described in this paper have been implemented as part of the CRIMSON hemodynamics software package.

Serological surveillance of H5 and H9 avian influenza A viral infections among pigs in southern China

2013 ◽  
Vol 64 ◽  
pp. 39-42 ◽  
Author(s):  
Zhaoxia Yuan ◽  
Wanjun Zhu ◽  
Ye Chen ◽  
Pei Zhou ◽  
Zhenpeng Cao ◽  
...  
Keyword(s):  
Avian Influenza ◽  
Influenza A ◽  
Viral Infections ◽  
Southern China ◽  
Serological Surveillance

Acute Pharyngitis: Etiology and Diagnosis

PEDIATRICS ◽  
1996 ◽  
Vol 97 (6) ◽  
pp. 949-954
Author(s):  
Alan L. Bisno
Keyword(s):  
Herpes Simplex ◽  
Influenza A ◽  
Epstein Barr Virus ◽  
Viral Infections ◽  
Clinical Manifestations ◽  
Acute Pharyngitis ◽  
Herpesvirus Type ◽  
Barr Virus ◽  
Epstein Barr

Acute pharyngitis may be caused by a wide variety of microbial agents (Table 1). The relative importance of each of these agents varies greatly depending on a number of epidemiologic factors, including age of the patient, season of the year, and geographic locale. Viruses Most cases of acute pharyngitis are viral in etiology and involve the pharynx as well as other portions of the respiratory tract as manifestations of the common cold, influenza, or croup. Examples include the rhinoviruses, coronaviruses, influenza A and B, and the parainfluenza viruses. Certain viral infections causing sore throat may exhibit clinical manifestations that are rather distinctive. Examples include enteroviruses (herpangina due to Coxsackie A), Epstein-Barr virus (infectious mononucleosis), cytomegalovirus (cytomegalovirus mononucleosis), adenovirus (pharyngoconjunctival fever, acute respiratory disease of military recruits), and herpes simplex virus (pharyngitis, gingivitis, and stomatitis). In many instances, however, the illnesses caused by these agents may overlap so broadly with that of streptococcal pharyngitis as to be clinically indistinguishable. Thus, Epstein-Barr virus, adenovirus, and herpes virus may all cause fever, exudative pharyngitis, and cervical adenitis. Several studies have documented the role of primary herpesvirus type 1 infection as a cause of acute pharyngitis in college students.1-4 Herpesvirus type 2 can occasionally cause a similar illness as a consequence of oral-genital sexual contact.5 Although herpesvirus infections may involve the anterior oral cavity (vesicular or ulcerative gingivostomatitis) as well as the posterior pharynx, they do not routinely do so. Only about one-fourth of students with culturally and serologically proven primary herpes simplex type 1 pharyngitis studied by Glezen et al,2 for example, had gingivostomatitis.

The comparative biochemistry of viruses and humans: an evolutionary path towards autoimmunity

2019 ◽  
Vol 400 (5) ◽  
pp. 629-638 ◽  
Author(s):  
Darja Kanduc
Keyword(s):  
Measles Virus ◽  
Influenza A ◽  
Viral Infections ◽  
Sequence Similarity ◽  
Eukaryotic Cell ◽  
Point Of View ◽  
Peptide Sequence ◽  
Human Viruses ◽  
Archaeal Ancestor ◽  
Borna Disease

Abstract Analyses of the peptide sharing between five common human viruses (Borna disease virus, influenza A virus, measles virus, mumps virus and rubella virus) and the human proteome highlight a massive viral vs. human peptide overlap that is mathematically unexpected. Evolutionarily, the data underscore a strict relationship between viruses and the origin of eukaryotic cells. Indeed, according to the viral eukaryogenesis hypothesis and in light of the endosymbiotic theory, the first eukaryotic cell (our lineage) originated as a consortium consisting of an archaeal ancestor of the eukaryotic cytoplasm, a bacterial ancestor of the mitochondria and a viral ancestor of the nucleus. From a pathologic point of view, the peptide sequence similarity between viruses and humans may provide a molecular platform for autoimmune crossreactions during immune responses following viral infections/immunizations.

Clinical use of Antiviral Drugs

1987 ◽  
Vol 21 (5) ◽  
pp. 399-405 ◽  
Author(s):  
Milap C. Nahata
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Antiviral Agent ◽  
Antiviral Drugs ◽  
Investigational Drug ◽  
Virus Infections ◽  
Herpes Encephalitis ◽  
Herpes Simplex Viruses ◽  
Varicella Zoster ◽  
Syncytial Virus

Remarkable progress has been made in antiviral chemotherapy. Six approved antiviral drugs are now available for the treatment of various viral infections. Trifluridine, idoxuridine and vidarabine are all effective in patients with herpes keratitis; trifluridine is preferred due to its low toxicity. Acyclovir is the drug of choice in patients with infections due to herpes simplex viruses, including genital herpes, herpes encephalitis, and neonatal herpes, and infections due to varicella-zoster virus. Amantadine is the only drug currently available for prophylaxis and treatment of influenza A, but an investigational drug, rimantadine, appears to be equally effective and less toxic than amantadine. Ribavirin is the most recently approved antiviral agent for the treatment of respiratory syncytial virus infections. Numerous antiviral drugs are being studied in patients with acquired immunodeficiency syndrome. Although currently available drugs have improved our ability to manage a variety of viral illnesses, much needs to be learned about specific dosage guidelines based on the studies of pharmacokinetics, pharmacodynamics, potential adverse effects and viral resistance, and the role of combination therapy to optimize therapy.

scholarly journals Acute non-atopic late-onset asthma induced by respiratory infection

2005 ◽  
pp. 53-57
Author(s):  
S. A. Sobchenko ◽  
O. S. Schetchikova ◽  
N. V. Yakovleva
Keyword(s):  
Respiratory Infection ◽  
Influenza A ◽  
Viral Infections ◽  
Late Onset ◽  
Lavage Fluid ◽  
Atopic Asthma ◽  
Influenza A Viruses ◽  
Asthma Patients ◽  
Bacterial Associations ◽  
Autumn And Winter

The aim of the study was to investigate features of respiratory infection inducing acute non-atopic late-onset asthma (NLA). Virologic and microbiologic examinations of brash biopsy samples of rhinopharyngeal and bronchial mucosa and bronchial lavage fluid were performed in 116 NLA patients admitted to a hospital in autumn and winter. The leading cause of acute NLA was found to be respiratory viral infections. We noted that different clinical NLA types had different sensibility to various viruses: adenoviruses mainly caused exacerbations of aspirin-induced asthma, respiratory syncytial and influenza A viruses were prevalently determined in non-atopic asthma. Patients with posttuberculotic lesions of the lungs mostly had viral and bacterial associations. Such mixed infection resulted in more severe and prolonged exacerbations of NLA.

scholarly journals Evaluation of the effectiveness of ARVI treatment regimen including etiotropic (enisamium iodide) and symptomatic treatment

2020 ◽  
Vol 92 (3) ◽  
pp. 50-55
Author(s):  
D. A. Lioznov ◽  
E. J. Karnaukhova ◽  
T. G. Zubkova ◽  
E. V. Shakhlanskaya
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Clinical Symptoms ◽  
Randomized Study ◽  
Antiviral Drug ◽  
Main Group ◽  
Average Score ◽  
Control Group ◽  
Symptomatic Therapy ◽  
Respiratory Viral Infections

Aim. To assess the effectiveness of the use of the antiviral drug enisamium iodide in the complex treatment of acute respiratory viral infections (ARVI) caused by various pathogens in routine clinical practice. Materials and methods. А prospective randomized study included 134 patients who were treated in the epidemic season of influenza and ARVI in 20182019. All patients were examined for the presence of influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, parainfluenza virus, coronaviruses, rhinoviruses, adenoviruses in nasopharyngeal swabs by PCR. Patients of the main group received enisamium iodide along with symptomatic therapy, the control group received only symptomatic therapy. The primary parameter of the effectiveness of therapy was evaluated on the scale of the general severity of the manifestations of ARVI (Total Symptom Score TSS) from the 2nd to the 4th day and by the secondary criteria of effectiveness: assessment of the duration of ARVI, the severity of fever, the proportion of patients with normal body temperature, the duration of the main clinical symptoms of acute respiratory viral infections, the proportion of patients in whom complications requiring antibiotics were noted, the dynamics of interferon status on the 6th day. To conduct a statistical analysis, depending on the efficiency parameter, the ANCOVA method with a fixed group factor and an initial score on the TSS severity scale was used as covariates, a criterion for comparing quantitative indicators in two independent groups. Results. According to the results of the analysis of the primary efficacy parameter, the median (interquartile range) of the average score on the scale of the general severity of ARVI manifestations in the main group was 4.33 (3.675.83), in the comparison group 6.00 (4.677.25; p0.001). The duration of systemic and local manifestations of acute respiratory viral infections was statistically significantly less in the main group (p=0.002 and p=0.019, respectively). Prescription of additional therapy was required in 2 (2.9%) patients of the main group (patients taking enisamium iodide), compared with 8 (11.9%) patients in the control group. Serum levels of interferon  and interferon  on the last day of treatment were statistically significantly higher in patients of the main group compared with the control group (p0.001). Treatment (excellent) was evaluated by 42 (62.7%) patients, while in the control group only 17 (25.8%) patients gave similar ratings. Both patients (p0.001) and doctors (p0.002) rated therapy tolerance better in the study group. Conclusion. The results confirmed the safety and effectiveness of enisamium iodide as a treatment for ARVI and influenza. The antiviral, interferonogenic and anti-inflammatory properties of the drug are involved in the formation of an antiviral response and reduce the risk of complications, which makes it possible to reduce the number of symptomatic agents used.

Sign in / Sign up

Export Citation Format

Share Document